Shares of Zydus Lifesciences are likely in focus after its subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatment for canine urinary incontinence in the U.S. The phenylpropanolamine hydrochloride tablets target aging and spayed female dogs, marking a significant move into the underserved animal generics market and reinforcing ZyVet’s focus on affordable, high-quality veterinary care.